HK Stock Market Move | TRANSTHERA-B(02617) surged over 25% when it announced the research data of tigotinib at the 2025 ESMO Annual Meeting and received an oral report.

TRANSTHERA-B (02617) rose by more than 25% at one point, and as of the time of writing, it has risen by 15.81% to 200 Hong Kong dollars, with a trading volume of 7.12 billion Hong Kong dollars. On the news front, according to a message from YJ Medicus, on October 20, YJ Medicus announced that at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting, the company publicly presented the latest summary research data on its core product Teligentanib in the indication of bile duct cancer. Teligentanib is a self-developed, registered clinical stage innovative multi-target small molecule kinase inhibitor that exerts anticancer effects by targeting tumor cells and improving the tumor microenvironment. Currently, Teligentanib has conducted multiple clinical trials for solid tumors such as bile duct cancer, prostate cancer, and breast cancer in China and the United States. It has received Orphan Drug Designation (ODD) for the treatment of bile duct cancer and Fast Track Designation for the treatment of prostate cancer from the U.S. FDA, as well as Fast Track Designation for the treatment of prostate cancer, inclusion in the breakthrough therapy designation list approved by China's NMPA, and Orphan Drug Designation (ODD) for the treatment of biliary tract cancer from the European EMA.